Medical University of South Carolina, SCTR Research Nexus
Welcome,         Profile    Billing    Logout  
 3 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flume, Patrick
STOP360AG, NCT05548283: Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Recruiting
4
730
Canada, US
Beta-lactam antibiotic, β-lactam, Aminoglycoside, AG
Chris Goss, University of Washington, Medical University of South Carolina, Cystic Fibrosis Foundation
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
11/26
11/26
MAC2v3, NCT03672630: Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Recruiting
2/3
500
Canada, US
Azithromycin, Zithromax, Ethambutol, Myambutol, Rifampin, Rifadin
Kevin Winthrop, Patient-Centered Outcomes Research Institute, National Jewish Health, The University of Texas Health Science Center at Tyler, University Health Network, Toronto, New York University, Medical University of South Carolina, Mayo Clinic, Louisiana State University Health Sciences Center in New Orleans, University of California, San Diego, Stanford University, University of Kansas, Vancouver Clinic, University of California, San Francisco, University of Washington, Johns Hopkins University, University of Miami, Emory University, University of Iowa, University of North Carolina, Temple University, Loma Linda University, Columbia University, University of Wisconsin, Madison, Northwell Health, Kaiser Permanente Hawaii, James A. Haley Veterans Administration Hospital
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
02/25
02/25
NCT05641298: Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Withdrawn
2
80
US
Sodium Fusidate, ACG-701, ARV-1801, Placebo
Aceragen
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
09/23
09/23
NCT05495243: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough

Completed
2
40
US
ARINA-1, Placebo
Renovion, Inc.
Non-cystic Fibrosis Bronchiectasis
01/24
03/24
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Recruiting
2
60
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
PTK0796-NTM-20203, NCT04922554: Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Active, not recruiting
2
75
US
Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets
Paratek Pharmaceuticals Inc
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
06/24
07/24
NCT05730283: Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Not yet recruiting
2
105
US
ORC-13661, Placebo
Kevin Winthrop, National Institute on Deafness and Other Communication Disorders (NIDCD), National Center for Advancing Translational Sciences (NCATS), Oricula Therapeutics, University of Washington, National Jewish Health, Mayo Clinic, The University of Texas Health Science Center at Tyler, Medical University of South Carolina
Ototoxicity, Drug-Induced
01/27
01/27
NCT05010577: Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

Active, not recruiting
1b/2a
32
Europe, US, RoW
BX004-A, Bacteriophage, Placebo, Vehicle buffer
BiomX, Inc.
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
10/23
03/24
HOPeCF, NCT06296394: Health Outcomes of Parents With Cystic Fibrosis-Aim 2

Recruiting
N/A
146
US
Parenthood
University of Pittsburgh, Cystic Fibrosis Foundation, National Heart, Lung, and Blood Institute (NHLBI)
Cystic Fibrosis, Parenthood Status
02/30
02/31
NCT05639556: Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

Recruiting
N/A
300
US
BMI and lean mass index from DXA, Anthropometric Measurements, Hand-grip strength, Six-minute walk Test, Sit-to-Stand Test, Short physical performance battery (SPPB), BIA Sub-study, Accelerometry to assess physical activity, Gastrointestinal (GI) and nutrition questionnaires:, Psychosocial questionnaire: PHQ-8, Psychosocial questionnaire: GAD-7, Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ), Psychosocial questionnaire: CF Fatalism Scale, Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA), 12-month Questionnaire, Oral glucose tolerance testing (OGTT), Continuous glucose monitoring (CGM), Chest CT scans (When available within the past 6 months in medical records), Hologic Dual X-Ray Absorptiometry (DXA), Ultrasound Sub-study of assessment of appendage muscles using ultrasound, Psychosocial questionnaire: Hunger Vital Sign questionnaire, Respiratory symptom questionnaire: CRISS, Spirometry, Psychosocial questionnaire: Additional Health Questionnaire
Jaeb Center for Health Research
Cystic Fibrosis
12/28
12/28

Download Options